Strategic Rationale – Agilent’s Acquisition of Proscia
End-to-End Pathology Integration: Combine Agilent’s staining instruments, reagents, and diagnostic assays with Proscia’s digital pathology and AI platform.
Build on Biocare Acquisition: Extend Agilent’s $950M Biocare acquisition with digital image management and AI capabilities.
Expand Market Reach: Cross-sell Proscia’s Concentriq software across Agilent’s established Dako customer base.
Advance Precision Medicine: Integrate pathology data with biomarker research and companion diagnostics.
Increase Recurring Revenue: Add subscription-based software revenue alongside existing instruments and consumables.
Capture Digital Pathology Growth: Capitalize on increasing AI adoption and digital pathology penetration, currently estimated at 20–30%.
Management Commentary Relevant to the Transaction
November 2025 — M&A as a Growth Strategy
Agilent emphasized acquisitions aligned with its long-term strategy and shareholder returns.
“We have capacity to do M&A, but we’re going to remain very disciplined, linked with our strategy.”
— Padraig McDonnell, President & CEO
February 2026 — Targeted Acquisition Strategy
Management reiterated its focus on acquisitions offering strategic fit and financial value.
“Simultaneously, we are focused on M&A targets that are both a strategic fit and financially attractive.”
— Padraig McDonnell, President & CEO
June 2026 — $950M Biocare Acquisition Completed
Agilent expanded its pathology portfolio with staining systems, antibodies, and reagents.
“We are pleased to complete our acquisition of Biocare, which represents a natural and strategic expansion of Agilent’s pathology portfolio and strengthens our ability to serve customers across clinical and research settings.”
— Padraig McDonnell, President & CEO
October 2026 — $270M Proscia Acquisition Announced
Agilent aims to expand its digital pathology and AI capabilities through Proscia.
“Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market”
— Padraig McDonnell, President & CEO
Proscia Overview
Business Model
Clinical SaaS: Annual subscriptions for digital pathology management, diagnostic review, and laboratory workflows.
Life Sciences Software: Enterprise licensing for pharmaceutical companies and CROs conducting biomarker research and clinical trials.
Data Solutions: Commercializes pathology datasets and patient insights for drug development and companion diagnostics.
Key Metrics
$18M+ — Trailing Twelve Months (TTM) Revenue, 2026
4,000+ — Hospitals & Clinics Served
16 of 20 — Top Pharmaceutical Companies Using Proscia
20%+ — Core Software Growth
Product Overview
Concentriq: FDA-cleared digital pathology software for slide management, AI-enabled analysis, and clinical diagnostics.
Proscia Aperture: Real-world data platform integrating pathology images with clinical, molecular, and genomic information.
Agilent–Proscia Partnership
Established Partnership: Four-year distribution relationship (2022–2026), preceding the acquisition.
Clinical Adoption: Joint digital pathology deployment at South Bend Medical Foundation in January 2026.
Commercialization & Integration: Concentriq offers 100+ laboratory information system integrations, while Proscia targeted 32,000 daily diagnostic cases by July 2025.
See the detailed Report Below